Frontlight ResearchEarly access
CompletedPhase 3
KIDS-STEP_Betamethasone Therapy in Hospitalised Children With CAP
Key facts
- Who runs it
- Julia Bielicki
- Where
- Germany and Switzerland13 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 3
- People taking part
- 510 people enrolled
- Started
- 28 Oct 2018
- Ended
- 26 Mar 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Celestamine®
- Record updated
- 24 February 2025
Who can take part
- Age
- 6 months to 14 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Body weight between 5 kg and 45 kg
- Admission to hospital (i.e. assignment of an inpatient case number)
- Clinical diagnosis of CAP (according to predefined criteria)
- Parent and/or child (as age-appropriate) willing to accept all possible randomised allocations and to be contacted by telephone weekly up to and including at 4 weeks after randomisation
- Informed consent form for trial participation signed by parent
Who cannot take part
- Inability to tolerate oral medication
- Completion of a course of systemic corticosteroids within 2 weeks from enrolment for courses of >5 days
- Participation in another study with investigational drug within the 30 days preceding and during the present study
- Previous enrolment into the current study
- Chronic underlying disease associated with an increased risk of very severe CAP or CAP of unusual aetiology
- Bilateral wheezing without focal chest signs AND clinical indication for primary administration of steroids (most likely to represent respiratory tract infection affecting the medium airways, i.e. not pneumonia)
- Documented allergy or any other known contraindication to any trial medication
- Subacute or chronic conditions requiring higher betamethasone equivalent or known primary or secondary adrenal insufficiency
- Known diabetes mellitus (type 1)
- Presence of local chest complications
- Admission to hospital with a primary clinical diagnosis of bronchiolitis
- Hospitalisation within the last two weeks preceding current admission with the possibility that pneumonia could be hospital-acquired or healthcare-associated
- Transfer for any reason to a non-participating hospital directly from the paediatric emergency department
- Parent are unlikely to be able to reliably participate in telephone follow-up because of significant language barriers
- Enrolment of the investigator, his/her family members, and other dependent persons
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to concurrently evaluate whether adjunct treatment with corticosteroids in children hospitalized with CAP is more effective in terms of the proportion of children reaching clinical stability and whether such adjunct treatment is no worse in terms of CAP relapse.
The 2 groups in the trial
- Celestamine® N 0.5Existing treatment, for comparison
oral betamethasone solution, once daily for two consecutive days at 0.1-0.2 mg/kg
Treatment: Celestamine®
- PlaceboPlacebo, for comparison
oral placebo matched to the product described above
Treatment: Celestamine®
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomised Placebo-controlled Multi-centre Effectiveness Trial of Adjunct Betamethasone Therapy in Hospitalised Children With Community Acquired Pneumonia (CAP)
- Publications
- Strikingly Decreased Community-acquired Pneumonia Admissions in Children Despite Open Schools and Day-care Facilities in Switzerland.The Pediatric infectious disease journal, 2021
- Randomised placebo-controlled multicentre effectiveness trial of adjunct betamethasone therapy in hospitalised children with community-acquired pneumonia: a trial protocol for the KIDS-STEP trial.BMJ open, 2020
- Record updated
- 24 February 2025